This week, cancer treatment and care are in the spotlight in the Innovation Partners BioBlog. Treatment for AML and new drugs to target various cancers are in the news in addition to the price transparency rule and findings related to Medicare charges. Read on for more in this week's Innovation
Drug Regulation, Release, Costs, and Approvals from Around the World
This week's Innovation Partners BioBlog focuses on moves that drug companies are making both here and abroad. Canada pushed back at President Trump's plans to import drugs from Canada. Novartis plans to open a gene cell therapy manufacturing plant in Stein, Switzerland, to eliminate costly and
Pushback Continues Against Medical Device Tax, More
The pushback continues against the impending enactment in 2020 of a tax on medical devices, part of the Affordable Care Act legislation that's been delayed for ten years. Humana reports favorable results with its Medicare Advantage plans and provides evidence that it both saves money and improves
Interesting Changes in ACA and Medicare Coverage Enrollment, More
This week’s Innovation Partners BioBlog examines two emerging trends: fewer people enrolling in the Affordable Care Act and more people choosing $0 premiums during Medicare enrollment. President Trump continues to push to mandate low drug prices while the drug makers push back. These and more are
Technology Transforms Healthcare Payment Models and Methods
This week, the Innovation Partners BioBlog looks are breaking articles on how technology can help the shift to new healthcare payment models. Voters agree that the soaring cost of drug prices should be curbed, but disagree on how to do so. CMS delayed its ruling to hospitals and healthcare providers
The Conversation about Rising Drug Prices
In this week’s Innovation Partners BioBlog, we look at many of the top stories highlighting the conversation about drug prices. Canada’s acting ambassador nixes the Trump Administration’s suggestion that Canadian drug imports will lower prices. Neulasta has another competitor as a third biosimilar
Healthcare Legislation, Drug Price Reduction, and More
In this week’s Innovation Partners BioBlog, we look at top stories impacting the world of healthcare especially those affected by politics and legislation. Senator Pelosi pushes for passage of her bill to lower drug prices but opponents believe it will stifle innovation and the development of new
FDA Generic Approvals Hit New Record, Humana Files Suit
This week in the Innovation Partners BioBlog, we look at several top stories including the record-breaking FDA approval rate for generic drugs. Human leveled serious charges against several pharmaceutical firms including Teva for price fixing, alleging up to 1,000% overcharge on some drugs including